PharmaDeals: PharmaDeals Review: Table of Contents

<< Previous Issue

Aug 2004 (Vol:2004, Issue: 50)

Next Issue >>

Download pdf of entire issue

Section: Business Commentaries
Europe's Need to Nurture Biotech Published: 1 Aug-2004
By: Fintan Walton
Abstract Fulltext:
Section: Company Profile
Oxford BioMedica plc Published: 4 Aug-2004
By: Business Review Editor
Abstract Fulltext:
Section: Deal Trackers
Plenaxis (abarelix) Published: 4 Aug-2004
By: Business Review Editor
Abstract Fulltext:
Section: Distribution & Marketing
Millennium Grants GSK European Marking Rights to Integrilin® Published: 4 Aug-2004
By: Business Review Editor
Abstract Fulltext:
Section: General
Vertex: An Accomplished Dealmaker Published: 4 Aug-2004
By: Business Review Editor
Abstract
Section: Licensing
Vernalis Licenses its Lead Compound for Parkinson’s disease to Biogen Idec Published: 4 Aug-2004
By: Business Review Editor
Abstract Fulltext:
CuraGen Licenses Seattle Genetics’ ADC Technology Published: 4 Aug-2004
By: Business Review Editor
Abstract Fulltext:
Section: Mergers & Acquisitions
Chromos to Acquire CellExSys and its T-Cell Technology Published: 4 Aug-2004
By: Business Review Editor
Abstract Fulltext:
Section: Research & Development
Merix and Kirin Collaborate on Dendritic Cell Vaccine Development Published: 4 Aug-2004
By: Business Review Editor
Abstract Fulltext:
Alnylam and Merck Sign Second RNAi Agreement in 10 Months Published: 4 Aug-2004
By: Business Review Editor
Abstract Fulltext:

Bookmark PharmaDeals through one of these social networks.

Table of Contents